文献速递前列腺癌

单孔机器人经膀胱部分前列腺切除术治疗局限性前列腺癌:初始系列及技术描述

Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique.
PubMed 文献 · Eur Urol · 2022-08-13

本文回顾性分析了9例低体积、局限性、低至中危前列腺癌(Gleason≤7)患者,由单一术者于2020年11月至2022年3月行单孔机器人经膀胱部分前列腺切除术,复制局灶治疗的入选标准。所有病例均无需额外端口或中转,无术中并发症,手术当日出院;6周时中位前列腺特异性抗原为0.5,中位男性性健康量表评分为17.5(术前为23),所有患者控尿。作者结论为该术式可行,早期功能结局显示控尿和勃起功能恢复时间令人印象深刻,需继续随访评估长期肿瘤学结局。

要点

  • 9例低至中危局限性前列腺癌患者行单孔机器人经膀胱部分前列腺切除术,均无额外端口或中转。
  • 无术中并发症,所有患者手术当日出院,6周时所有患者控尿。
  • 6周时中位前列腺特异性抗原0.5,中位男性性健康量表评分17.5(术前23)。

核心结论

  • 作者 demonstrated 单孔机器人经膀胱部分前列腺切除术的可行性,早期功能结局显示控尿和勃起功能恢复时间令人印象深刻,需继续随访评估长期肿瘤学结局。

研究设计与样本

  • 回顾性分析9例低体积、局限性、低至中危前列腺癌(Gleason≤7)患者,由单一术者于2020年11月至2022年3月行单孔机器人经膀胱部分前列腺切除术,复制局灶治疗的入选标准。

主要发现

  • 所有病例均无需额外端口或中转完成,无术中并发症,所有患者手术当日出院。
  • 病理显示Gleason评分3+3=6者1例,3+4=7者7例,4+3=7者1例,术中切缘评估均为阴性。
  • 6周时中位前列腺特异性抗原为0.5,中位男性性健康量表评分为17.5(术前为23)。
  • 6周时所有患者控尿。

局限性

  • 局限性包括患者数量少、随访时间短和单一术者经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Partial prostatectomy has been described as an alternative to focal therapy for the management of localized low- and intermediate-risk prostate cancer. OBJECTIVE: To describe early outcomes and technique for single-port (SP) transvesical partial prostatectomy. DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis was performed for nine patients with low-volume, localized, low- to intermediate-risk prostate cancer (Gleason ≤7) undergoing SP transvesical partial prostatectomy replicating the inclusion criteria for focal therapy by a single surgeon from November 2020 to March 2022. SURGICAL PROCEDURE: The daVinci SP access port was inserted percutaneously into the bladder and pnuemovesicum was achieved. The camera, robotic instruments, assistant port, and flexible suction tubing were introduced through the access port. The Koelis transrectal ultrasound with preoperative prostate magnetic resonance imaging fusion was used for intraoperative guidance. MEASUREMENTS: Demographic information, intraoperative variables, and postoperative outcomes were collected in an institutional review board-approved database, and a descriptive statistical analysis was performed. RESULTS AND LIMITATIONS: All cases were completed without requiring extra ports or conversion. No intraoperative complications were noted, and all patients were discharged on the day of surgery. Pathology showed Gleason scores of 3 + 3 = 6 in one case, 3 + 4 = 7 in seven cases, and 4 + 3 = 7 in one case, all with negative intraoperative margin assessment. At 6 wk, the median prostate-specific antigen was 0.5 and the median Sexual Health Inventory for Men score was 17.5 from 23 preoperatively. All patients were continent at 6 wk. The limitations include a small number of patients, short follow-up, and single-surgeon experience. CONCLUSIONS: We demonstrated the feasibility of the SP robotic transvesical partial prostatectomy. Early functional outcomes show impressive time to continence and erectile function. Continued follow-up will evaluate long-term oncologic outcomes. PATIENT SUMMARY: We performed partial prostatectomies in selected patients as an alternative to focal therapy using a novel transvesical single-port approach. Our approach was safe and feasible, with fewer complications and promising initial return to continence and erectile function.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Kaouk JH, Ferguson EL, Beksac AT, et al. Single-port Robotic Transvesical Partial Prostatectomy for Localized Prostate Cancer: Initial Series and Description of Technique. Eur Urol. 2022. PMID: 35970657. doi:10.1016/j.eururo.2022.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。